

**CANCER TREATMENT AGENT CONTAINING INHIBITOR OF
SPHINGOLYCOLIPID METABOLISM AS EFFECTIVE COMPONENT****Publication number:** JP1254623**Publication date:** 1989-10-11**Inventor:** NOOMAN ESU RADEIN; INOKUCHI JINICHI**Applicant:** UNIV MICHIGAN**Classification:**

- international: *A61K45/00; A61K31/165; A61K31/535; A61K31/5375;
A61P3/00; A61P35/00; C07D295/12; A61K45/00;
A61K31/165; A61K31/535; A61K31/5375; A61P3/00;
A61P35/00; C07D295/00; (IPC1-7): A61K31/165;
A61K45/00; C07C103/38*

- European: A61K31/535

Application number: JP19880152065 19880620**Priority number(s):** US19880176920 19880404**Also published as:**

US5041441 (A1)

Report a data error here

Abstract of JP1254623

PURPOSE: To prepare a therapeutic agent for cancers comprising an inhibitor of the sphingoglycolipid metabolism as an active ingredient without suppressing functions of the bone marrow and systems related thereto. **CONSTITUTION:** This therapeutic agent for cancers comprises an inhibitor of the sphingoglycolipid metabolism, preferably a compound represented by the formula (R is an aromatic ring, cyclohexane or a 10-15C aliphatic group; R<1> is an amine; R<2> is a 9-17C aliphatic group) and its therapeutically permissible salt, e.g. D-, L and DL-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol as an active ingredient. The therapeutic agent can further be used for treating non-malignant diseases caused by cell proliferation such as benign tumors, warts and skin growth, preventing the fetal growth and terminating undesirable pregnancy.

.....
Data supplied from the **esp@cenet** database - Worldwide